Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Police say violent crime improving in downtown Raleigh, but more work is needed
Recommended
Back to school guide: Buses, lunches, key dates
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
PepGen Inc. - Common Stock
(NQ:
PEPG
)
9.440
+0.370 (+4.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
122,599
Open
9.080
Bid (Size)
9.260 (1)
Ask (Size)
10.62 (7)
Prev. Close
9.070
Today's Range
9.080 - 9.500
52wk Range
3.720 - 19.30
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 11, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
PEPG Stock Earnings: PepGen Misses EPS for Q2 2024
August 08, 2024
PEPG stock results show that PepGen missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
+33.15%
+33.15%
1 Month
-47.14%
-47.14%
3 Month
-28.27%
-28.27%
6 Month
-32.04%
-32.04%
1 Year
+40.27%
+40.27%
More News
Read More
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 08, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 02, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
PEPG Stock Earnings: PepGen Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023
March 06, 2024
Via
InvestorPlace
Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher
July 31, 2024
Via
Benzinga
Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings
July 31, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm
July 31, 2024
From
The Schall Law Firm
Via
Business Wire
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
July 30, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
July 02, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Announces Executive Team Promotions
June 11, 2024
From
PepGen Inc.
Via
Business Wire
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024
From
PepGen Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 12, 2024
Via
Benzinga
Insiders Buying GameStop And 2 Other Stocks
April 10, 2024
Via
Benzinga
PepGen to Participate in Upcoming Investor Conferences
March 13, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 13, 2024
From
PepGen Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
March 07, 2024
Via
Benzinga
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
March 06, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
March 04, 2024
From
PepGen Inc.
Via
GlobeNewswire
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
February 20, 2024
From
PepGen Inc.
Via
GlobeNewswire
Over $37M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying
February 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 07, 2024
Via
Benzinga
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
February 07, 2024
From
PepGen Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.